Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Elsibucol (AGI 1096) 是一种VCAM1抑制剂,可用于研究器官移植排斥。Elsibucol 是一种代谢稳定的丙醇衍生物,具有抗氧化、抗炎和抗增殖的特性。它能降低血液中的胆固醇水平,减少受伤动脉中的氧化应激和炎症反应,从而抑制动脉粥样硬化,保护动脉损伤后的内皮愈合。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 990 | 现货 | ||
5 mg | ¥ 2,470 | 现货 | ||
10 mg | ¥ 3,700 | 现货 | ||
25 mg | ¥ 5,970 | 现货 | ||
50 mg | ¥ 8,260 | 现货 | ||
100 mg | ¥ 10,900 | 现货 | ||
500 mg | ¥ 22,300 | 现货 |
产品描述 | Elsibucol (AGI 1096) is a VCAM1 inhibitor for the study of organ transplant rejection.Elsibucol is a metabolically stable propanol derivative with antioxidant, anti-inflammatory and anti-proliferative properties. It lowers blood cholesterol levels and reduces oxidative stress and inflammatory responses in injured arteries, thereby inhibiting atherosclerosis and protecting endothelial healing after arterial injury. |
体外活性 | AGI-1096 (0-20 μM) inhibited the inducible expression of vascular cell adhesion molecule (VCAM)-1, E-selectin, and monocyte chemoattractant protein (MCP)-1 in endothelial cells and tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta secretion from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells. It also inhibited the serum-stimulated proliferation of aortic smooth muscle cells.[4] |
体内活性 | Elsibucol (0.5%, 1%; feed; arterial injury in rabbits with hypercholesterolemia; 3 weeks) significantly decreases blood total cholesterol, LDLc, and triglyceride levels. This is associated with a significant 46% reduction of neointimal hyperplasia following arterial injury. Interestingly, the effect of Elsibucol on cholesterol levels and neointimal formation appears to be more pronounced than that of probucol. Treatment with Elsibucol is associated with a significant reduction of cellular proliferation (PCNA immunostaining), oxidative stress (nitrotyrosine immunostaining), VCAM-1 expression, and macrophage infiltration in injured arteries. Despite its potent effect on neointimal hyperplasia, Elsibucol does not prevent endothelial healing (Evans blue staining) following arterial injury. CONCLUSIONS: In hypercholesterolemic animals, Elsibucol inhibits atherosclerosis and preserves endothelial healing following arterial injury.[1] |
别名 | AGI-1096, UNII-O7T92N1Y8T, AGI 1096 |
分子量 | 602.93 |
分子式 | C35H54O4S2 |
CAS No. | 216167-95-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (82.93 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.6586 mL | 8.2928 mL | 16.5857 mL | 41.4642 mL |
5 mM | 0.3317 mL | 1.6586 mL | 3.3171 mL | 8.2928 mL | |
10 mM | 0.1659 mL | 0.8293 mL | 1.6586 mL | 4.1464 mL | |
20 mM | 0.0829 mL | 0.4146 mL | 0.8293 mL | 2.0732 mL | |
50 mM | 0.0332 mL | 0.1659 mL | 0.3317 mL | 0.8293 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Elsibucol 216167-95-2 oxidation-reduction Antioxidant AGI1096 AGI-1096 UNII-O7T92N1Y8T AGI 1096 Inhibitor inhibitor inhibit